# A Study of YM178 in Subjects With Symptoms of Overactive Bladder

> **NCT01043666** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 1126 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** YM178
- **DRUG:** Placebo
- **DRUG:** tolterodine ER

## Key facts

- **NCT ID:** NCT01043666
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-21
- **Primary completion:** 2011-09-16
- **Final completion:** 2011-09-16
- **Target enrollment:** 1126 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01043666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01043666, "A Study of YM178 in Subjects With Symptoms of Overactive Bladder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01043666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*